Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

CRESCENDO Investigators; Eric J Topol; Marie-Germaine Bousser; Keith A A Fox; Mark A Creager; Jean-Pierre Despres; J Donald Easton; Christian W Hamm; Gilles Montalescot; P Gabriel Steg; Thomas A Pearson; Eric Cohen; Christophe Gaudin; Bernard Job; Judith H Murphy; Deepak L Bhatt

doi:10.1016/S0140-6736(10)60935-X

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

CRESCENDO Investigators, Eric J Topol, Marie-Germaine Bousser, Keith A A Fox, Mark A Creager, Jean-Pierre Despres, J Donald Easton, Christian W Hamm, Gilles Montalescot, P Gabriel Steg, Thomas A Pearson, Eric Cohen, Christophe Gaudin, Bernard Job, Judith H Murphy, Deepak L Bhatt

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival.

Original language	English
Pages (from-to)	517-23
Number of pages	7
Journal	The Lancet
Volume	376
Issue number	9740
DOIs	https://doi.org/10.1016/S0140-6736(10)60935-X
Publication status	Published - 2010

Access to Document

10.1016/S0140-6736(10)60935-X

Cite this

CRESCENDO Investigators, Topol, E. J., Bousser, M.-G., Fox, K. A. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., Cohen, E., Gaudin, C., Job, B., Murphy, J. H., & Bhatt, D. L. (2010). Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. The Lancet, 376(9740), 517-23. https://doi.org/10.1016/S0140-6736(10)60935-X

@article{240b2bdad51e45b6afd6e03c803a67ba,

title = "Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial",

abstract = "Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival.",

author = "{CRESCENDO Investigators} and Topol, {Eric J} and Marie-Germaine Bousser and Fox, {Keith A A} and Creager, {Mark A} and Jean-Pierre Despres and Easton, {J Donald} and Hamm, {Christian W} and Gilles Montalescot and Steg, {P Gabriel} and Pearson, {Thomas A} and Eric Cohen and Christophe Gaudin and Bernard Job and Murphy, {Judith H} and Bhatt, {Deepak L}",

year = "2010",

doi = "10.1016/S0140-6736(10)60935-X",

language = "English",

volume = "376",

pages = "517--23",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9740",

}

CRESCENDO Investigators, Topol, EJ, Bousser, M-G, Fox, KAA, Creager, MA, Despres, J-P, Easton, JD, Hamm, CW, Montalescot, G, Steg, PG, Pearson, TA, Cohen, E, Gaudin, C, Job, B, Murphy, JH & Bhatt, DL 2010, 'Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial', The Lancet, vol. 376, no. 9740, pp. 517-23. https://doi.org/10.1016/S0140-6736(10)60935-X

TY - JOUR

T1 - Rimonabant for prevention of cardiovascular events (CRESCENDO)

T2 - a randomised, multicentre, placebo-controlled trial

AU - CRESCENDO Investigators

AU - Topol, Eric J

AU - Bousser, Marie-Germaine

AU - Fox, Keith A A

AU - Creager, Mark A

AU - Despres, Jean-Pierre

AU - Easton, J Donald

AU - Hamm, Christian W

AU - Montalescot, Gilles

AU - Steg, P Gabriel

AU - Pearson, Thomas A

AU - Cohen, Eric

AU - Gaudin, Christophe

AU - Job, Bernard

AU - Murphy, Judith H

AU - Bhatt, Deepak L

PY - 2010

Y1 - 2010

N2 - Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival.

AB - Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival.

UR - http://www.scopus.com/inward/record.url?scp=77956017429&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)60935-X

DO - 10.1016/S0140-6736(10)60935-X

M3 - Article

C2 - 20709233

SN - 0140-6736

VL - 376

SP - 517

EP - 523

JO - The Lancet

JF - The Lancet

IS - 9740

ER -

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

Abstract / Description of output

Access to Document

Other files and links

Fingerprint

Cite this